Use of cookies

Lund University uses cookies to ensure that the website functions properly and to improve your experience.

Read more in our cookie policy

Search results

Filter

Reset filter

Filetype

Your search for "*" yielded 116667 hits

Axel Hyrenius Wittsten

 The immune system has a remarkable capacity to scan tissues to recognize and eliminate abnormal and malignant cells. Scientific advances now allow us to improve and utilize this strength of the immune system against tumors.Our goal is to advance our ability to treat cancer using cell-based immunotherapy. By developing state-of-art genetic circuits and synthetic biology we strive to bring forward

https://www.clinicalgenetics.lu.se/axel-hyrenius-wittsten - 2025-08-03

Fioretos' Research Group

Translating genomic discoveries into improved clinical decision making, mechanistic understanding, and therapy of acute leukemia The overall objective of our research is to significantly improve the way in which acute leukemia is diagnosed, understood at the functional/molecular level, and treated within health care.We work in three highly aligned and synergistic projects. In the first, new and cl

https://www.clinicalgenetics.lu.se/division-clinical-genetics/fioretos-research-group - 2025-08-03

Järås' Research Group

  With a basis in stem cell biology, genetics, immunology and cancer research, our mission is to develop innovative immunotherapies that effectively target leukemia and other malignancies. To achieve this goal, we work on the following projects:•    Unravel immune evasion mechanisms in cancer. •    Development of therapeutic antibodies directed to novel targets.•    Development of CAR-macrophages

https://www.clinicalgenetics.lu.se/division-clinical-genetics/jaras-research-group - 2025-08-03

Anna Hagström

  We focus on understanding the pathogenetic mechanisms underlying leukemogenesis with a special focus on infant leukemia. In particular we are interested in unravelling the biological mechanisms that drive clonal evolution, the emergence of drug resistance, and the role of tumor heterogeneity in these processes, ultimately leading to new effective therapies. We use a combination of state-of-the-a

https://www.clinicalgenetics.lu.se/division-clinical-genetics/anna-hagstrom - 2025-08-03

Cancer Cell Evolution

    We make genetic and functional maps of cancer cell evolution in patients by analysing multiple tumour samples from the same patient. In particular, we focus on childhood cancer where we try to unravel the genetic mechanisms leading to relapse and treatment resistance.To achieve our aim, we use methods from species evolution (phylogenetics) to reconstruct the evolutionary history of individual

https://www.clinicalgenetics.lu.se/division-clinical-genetics/cancer-cell-evolution - 2025-08-03

Database of Chromosome Aberrations and Gene Fusions in Cancer

The Database of Chromosome Aberrations and Gene Fusions in Cancer, established in 1980, is an attempt to register systematically all published cytogenetic aberrations reported in cancer, including patient and tumor characteristics, gene fusions identified by cytogenetics or massively parallel sequencing, and studies pertaining to the clinical relevance of cytogenetic aberrations and/or gene rearra

https://www.clinicalgenetics.lu.se/division-clinical-genetics/database-chromosome-aberrations-and-gene-fusions-cancer - 2025-08-03

The Genetics of Soft Tissue Tumors

  Soft tissue tumors (STT) constitute a heterogeneous group of approximately 100 distinct neoplasms, including more than 50 malignant subtypes, so-called sarcomas. Genetic analyses have shown that the clinical and biological variation among these neoplasms is reflected in their genotypes. While the diagnosis of STT has been improved by such genetic biomarkers, the use of genetic information for im

https://www.clinicalgenetics.lu.se/division-clinical-genetics/genetics-soft-tissue-tumors - 2025-08-03

Genetics/Epigenetics of Pediatric Leukemia

The goal of our research is to increase our understanding of the leukemogenic process and to investigate the clinical impact of genetic/epigenetic abnormalities in pediatric acute lymphoblastic and myeloid leukemia. In order to achieve this goal, we use several types of “next generation sequencing”, such as whole genome sequencing, whole exome sequencing, and RNA sequencing, and various methylatio

https://www.clinicalgenetics.lu.se/division-clinical-genetics/geneticsepigenetics-pediatric-leukemia - 2025-08-03

Aneuploidy in Cancer

   Gains and losses of whole chromosomes, termed aneuploidy, is seen in at least half of all tumors. How it affects tumorigenesis is still poorly understood. We use hyperdiploid (51-67 chromosomes) pediatric acute lymphoblastic leukemia (ALL) as a model to study aneuploidy, focusing on:How does the cell become aneuploid? We use large-scale sequencing and array-based analyses of bulk and single cel

https://www.clinicalgenetics.lu.se/division-clinical-genetics/aneuploidy-cancer - 2025-08-03

Complex Genomes in Cancer

The highly complex genome of an osteosarcoma.Our aim is to develop new treatment strategies for patients with highly aggressive malignancies. To this end, we screen clinical tumor material for disease-causing mutations using deep sequencing technology and we manipulate genes of interest in cancer model systems to understand the true consequences of mutations.Most high-grade cancers harbor mutation

https://www.clinicalgenetics.lu.se/division-clinical-genetics/complex-genomes-cancer - 2025-08-03